

REMARKS

Claims 1-37 are pending. Claims 24-37 were previously withdrawn. Claims 1, 15 and 24 were previously amended in Applicants' February 11, 2009 Amendment/Reply ("Applicants' February 11th Reply"). No new matter was added as previously presented in Applicants' February 11th Reply.

1. Elected and Examined Subject Matter

Again, Applicants thank the United States Patent and Trademark Office ("the Office") for examining the elected subject matter, and acknowledge the Office has expanded the examination beyond the elected subject matter to the provisionally elected subject matter. See Applicants' February 11th Reply.

a. Claims 1-4, 6-7, 10, 12, 15, 17-18, and 21-23

The Office has provisionally objected to claims 1-4, 6-7, 10, 12, 15, 17-18, and 21-23, for containing elected and non-elected subject matter. See page 6 of the Final Office Action. However, Applicants respectfully offer that the objection is moot since the non-elected subject matter examined is novel as discussed in Applicants' February 11th Reply. As previously presented then, Applicants will consider amending the claims with respect to non-examined, non-elected subject matter if the claims are deemed allowable otherwise.

2. Claims are Novel

a. Claims 1-4, 6, 10, 12, 17, 21 and 23

The Office has rejected claims 1-4, 6, 10, 12, 17, 21 and 23 under 35 U.S.C. 102(b) for allegedly being unpatentable over International Application Publication No. WO2000/017190 by Auvin et al., which has a U.S. equivalent – namely, U.S. Patent No. 6,653,312 (hereinafter referred to together as, "the '190 publication", unless specifically noted otherwise). Applicants traverse the rejection and respectfully request it be reversed for the reasons put forth in Applicants' February 11th Reply. See Applicants' February 11th Reply.

b. Claims 2-4, 6-7, 10, 12, 15, 17-18, and 21-23

The Office has objected to claims 2-4, 6-7, 10, 12, 15, 17-18, and 21-23 for being dependent on rejected claim 1. Because of the reasons put forth in Applicants' February 11th

Application Serial No. 10/551,738 (Attorney Docket No. 429-US-PCT)

Request for Continued Examination Amendment/Reply

Dated: April 23, 2009

Page 21 of 21

Reply, claim 1 is novel and the rejection of claim 1 should be reversed. Accordingly, this objection also should be reversed.

3. Conclusion

Because of the foregoing, the instant claimed compounds are novel and believed in condition for allowance. Early reconsideration and allowance of all pending claims is respectfully requested.

The Commissioner is hereby authorized to charge any fee or credit to Deposit Account No. 503201. The Office is requested to contact the undersigned if an interview would facilitate allowance of the claims.

Respectfully submitted,

Lundbeck Research USA, Inc.
215 College Road
Paramus, New Jersey 07652
(201) 261-1331 Ext. 790

/Margaret M. Buck, Reg. #54,010/
Margaret M. Buck, Esq.
Registration No. 54,010